Pleuropneumonia (Bacterial)

Pleuropneumonia is a severe bacterial infection affecting both the lung tissue (pneumonia) and the pleural space surrounding the lungs (pleuritis), representing one of the most serious respiratory conditions affecting horses. This combination of deep lung infection with pleural involvement creates significant respiratory compromise and systemic illness that requires aggressive medical intervention and often surgical drainage to achieve successful resolution. The condition frequently develops as a complication of primary bacterial pneumonia when infection extends beyond the lung parenchyma to involve the pleural membranes, causing fluid accumulation, fibrin deposition, and adhesion formation.

Pleuropneumonia occurs worldwide and is strongly associated with transportation stress, earning it the common names shipping fever and travel sickness. Horses that have recently undergone long-distance transport, particularly those traveling with heads elevated preventing normal airway drainage, face dramatically increased risk. The condition affects horses of all ages, breeds, and disciplines, though sport horses, racehorses, and show horses that travel frequently for competition have higher incidence due to repeated exposure to transport-related risk factors.

The impact of pleuropneumonia on equine health is substantial, with mortality rates ranging from ten to thirty percent even with aggressive treatment. Survivors often face prolonged recovery periods of months rather than weeks, with significant economic consequences from treatment costs, lost training time, and potential permanent reduction in athletic capacity. Pleural adhesion formation may restrict lung expansion long after infection resolves, limiting respiratory function during exercise. The psychological and financial toll on owners managing horses through extended treatment and recovery should not be underestimated.

Treatability of pleuropneumonia requires early recognition, aggressive intervention, and sustained commitment to extended treatment protocols. Success depends heavily on how quickly appropriate therapy begins, with horses treated early in the disease course having significantly better outcomes than those presenting with established infection and extensive pleural involvement. Modern treatment approaches combining systemic antibiotics, pleural drainage, lavage, and supportive care have improved survival rates substantially compared to historical outcomes. Owner awareness of early warning signs, particularly following transport, enables the prompt veterinary evaluation essential for optimal outcomes.

The primary causes of bacterial pleuropneumonia involve opportunistic bacteria that gain access to the lower respiratory tract and establish infection when normal host defenses are compromised. The most commonly isolated organisms include Streptococcus equi subspecies zooepidemicus, Pasteurella species, Escherichia coli, Actinobacillus species, and various anaerobic bacteria. Mixed infections involving multiple bacterial species are common, reflecting the opportunistic nature of the disease. These organisms often exist as normal inhabitants of the equine upper respiratory tract, becoming pathogenic when conditions favor their multiplication and invasion of deeper tissues.

No genetic or breed predisposition has been established for pleuropneumonia, as the condition results from environmental and management factors rather than inherited susceptibility. All breeds develop pleuropneumonia at similar rates when exposed to equivalent risk factors. Individual variation in immune function may influence susceptibility, with horses having compromised immunity from any cause at increased risk. Prior respiratory illness may damage airways and impair defenses, predisposing to future episodes of bacterial pneumonia and pleuropneumonia.

Environmental and management factors play dominant roles in pleuropneumonia development, with transportation representing the single most important risk factor. Long-distance travel, particularly exceeding twelve hours, dramatically increases risk through multiple mechanisms. Horses transported with heads restrained in elevated positions cannot lower their heads to allow normal mucociliary drainage of the respiratory tract, causing secretion accumulation. Stress from transport suppresses immune function while exposure to exhaust fumes, dust, and temperature fluctuations irritates airways. Crowded conditions during transport may increase exposure to pathogenic organisms.

Risk factors beyond transport include recent viral respiratory infection that damages respiratory epithelium, general anesthesia that impairs normal airway clearing mechanisms, esophageal obstruction (choke) that may lead to aspiration, and any cause of immunosuppression. Horses undergoing surgery requiring general anesthesia have elevated pleuropneumonia risk in the post-operative period. Poor ventilation in stabling, dusty environments, and concurrent illness increase susceptibility. Inadequate rest following transport or viral infection before returning to training predisposes to bacterial complications.

The pathophysiology of pleuropneumonia involves initial bacterial colonization of compromised lower airways, followed by multiplication and extension of infection. Inflammatory response to bacterial invasion causes lung consolidation, impaired gas exchange, and systemic illness. Extension of infection to the visceral pleura leads to inflammation of the pleural membranes with exudation of inflammatory fluid into the pleural space. This pleural effusion further compromises respiratory function by restricting lung expansion. Continued inflammation leads to fibrin deposition and organization into fibrous adhesions that may permanently limit lung function.

Early warning signs of pleuropneumonia may be subtle and easily missed, particularly in the early post-transport period when mild depression might be attributed to travel fatigue. Initial symptoms often include slightly elevated body temperature, mild decrease in appetite, and subtle changes in respiratory pattern that careful observation can detect. Horses may appear less energetic than usual and show reluctance to move freely. Because horses naturally mask illness, early detection requires attentive daily observation of normal behavior patterns to recognize departures from baseline. Temperature monitoring in the days following transport provides objective data for early fever detection.

Common symptoms of established pleuropneumonia include fever often ranging from 102 to 106 degrees Fahrenheit, marked depression, and complete or near-complete loss of appetite. Nasal discharge typically becomes apparent, progressing from serous to mucopurulent as infection advances. Coughing may be present but is sometimes minimal despite severe lung involvement, as the presence of pleural fluid may limit the cough reflex. Weight loss occurs rapidly due to reduced feed intake combined with the metabolic demands of fever and infection.

Behavioral changes associated with pleuropneumonia reflect both respiratory compromise and systemic illness. Affected horses typically stand quietly with little interest in their surroundings, handlers, or herd mates. They may refuse feed entirely or pick at food without consuming significant amounts. Reluctance to lie down is common, as recumbency increases respiratory effort when lungs are compromised. Some horses show reluctance to turn or move, adopting a stiff gait to minimize chest wall movement that causes pain from inflamed pleural surfaces. Water consumption may decrease, contributing to dehydration.

Physical signs detectable on examination include increased respiratory rate and effort, often with flared nostrils during inspiration. A characteristic finding is a grunt or groan at the end of expiration, reflecting the pain of breathing with pleural inflammation. Auscultation reveals abnormal lung sounds in affected areas, with crackles, wheezes, or absence of normal sounds over consolidated lung or fluid accumulation. Heart rate is typically elevated, often above fifty beats per minute. Poor pulse quality, prolonged capillary refill time, and dark or toxic-appearing mucous membranes indicate systemic toxemia.

Symptom progression in untreated or severe pleuropneumonia follows an alarming course of worsening respiratory compromise and systemic deterioration. Fever may initially spike then become variable as infection becomes chronic. Respiratory effort increases as fluid accumulates in the pleural space, restricting lung expansion. Weight loss becomes dramatic, with affected horses losing condition rapidly despite intravenous nutritional support. Dependent edema may develop as protein levels drop from systemic inflammation. Without intervention, septic shock, respiratory failure, or multi-organ dysfunction may prove fatal.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress at rest, extreme depression or inability to rise, very high fever exceeding 105 degrees Fahrenheit, complete refusal to eat or drink, signs of shock including rapid heart rate and poor perfusion, or rapid deterioration from previously stable condition. Any horse developing respiratory symptoms within days of transport should receive urgent evaluation. Horses showing the characteristic expiratory grunt of pleuritis require immediate assessment and likely referral to a facility capable of intensive care and thoracic drainage.

Physical examination provides essential initial assessment for suspected pleuropneumonia, with findings often clearly indicating serious respiratory disease. Vital sign assessment typically reveals fever, tachycardia, and tachypnea, often with increased respiratory effort visible as flared nostrils and enhanced thoracic and abdominal movement during breathing. The characteristic expiratory grunt heard in many cases strongly suggests pleural involvement. Thoracic auscultation identifies areas of abnormal or absent lung sounds, with fluid accumulation producing dull sounds ventrally. Pain on chest compression helps confirm pleuritis. Overall appearance including depression, weight loss, and dehydration indicates systemic illness severity.

Diagnostic tests for pleuropneumonia include complete blood count, serum chemistry, and fibrinogen measurement. White blood cell count may be elevated, normal, or decreased depending on disease stage, with left shift indicating active infection and toxic changes in neutrophils suggesting systemic toxemia. Fibrinogen is typically markedly elevated, often exceeding 600 milligrams per deciliter, reflecting significant inflammation. Serum chemistry assesses organ function and protein levels, with hypoalbuminemia common in chronic cases. Arterial blood gas analysis reveals hypoxemia in severely affected horses.

Advanced diagnostics essential for pleuropneumonia evaluation and management include thoracic ultrasound and radiography. Ultrasound examination of the thorax is particularly valuable, allowing real-time visualization of pleural fluid accumulation, assessment of fluid character (anechoic versus cellular and echogenic), and identification of fibrin strands or loculations. Ultrasound guides thoracocentesis for fluid sampling and drainage. Thoracic radiography reveals pulmonary infiltrates, consolidation patterns, and may show pleural effusion lines. Analysis of pleural fluid obtained by thoracocentesis provides crucial diagnostic information including cell counts, protein levels, glucose concentration, and bacterial culture with sensitivity testing.

Differential diagnosis for pleuropneumonia includes uncomplicated bacterial pneumonia without pleural involvement, which may represent an earlier stage of the same disease process. Hemothorax from trauma produces pleural fluid accumulation but with different fluid characteristics. Neoplasia affecting the thorax rarely may cause pleural effusion. Cardiac disease with pericardial effusion may produce some similar findings. The combination of recent transport history, systemic illness, and characteristic thoracic ultrasound findings usually allows confident diagnosis. Bacterial culture from transtracheal wash or pleural fluid identifies causative organisms and guides antibiotic selection.

Emergency and immediate treatment of pleuropneumonia focuses on respiratory stabilization, fluid resuscitation, and initiation of antimicrobial therapy. Horses with severe respiratory compromise may require oxygen supplementation to maintain adequate blood oxygen levels. Intravenous fluid therapy corrects dehydration, supports circulation, and facilitates toxin elimination. Broad-spectrum antibiotic therapy should begin immediately pending culture results, typically combining a penicillin with an aminoglycoside to cover the gram-positive, gram-negative, and anaerobic organisms commonly involved. Anti-inflammatory medications reduce fever, control inflammation, and provide comfort.

Medical management of pleuropneumonia requires prolonged antibiotic therapy, typically lasting four to eight weeks or longer depending on response. Initial intravenous antibiotic administration transitions to oral medications as clinical improvement allows, though some cases require extended intravenous therapy. Antibiotic selection should be guided by culture and sensitivity results when available, with adjustments made if initial empirical therapy proves inadequate. Metronidazole or other anaerobic coverage is often added given the frequency of anaerobic involvement. Anti-inflammatory therapy continues throughout acute illness, with appropriate medication selection balancing efficacy against potential adverse effects.

Surgical intervention through thoracic drainage represents a cornerstone of pleuropneumonia treatment for horses with significant pleural effusion. Thoracocentesis using large-bore needles or chest tubes allows removal of infected fluid that harbors bacteria, impairs lung expansion, and contributes to adhesion formation. Indwelling chest drains facilitate repeated drainage and pleural lavage with sterile saline to remove fibrin and debris. Thoracoscopy provides direct visualization for cases with loculated fluid or extensive adhesions. Aggressive drainage combined with antimicrobial therapy significantly improves outcomes compared to antibiotics alone.

Supportive care during pleuropneumonia treatment addresses multiple organ systems affected by this systemic illness. Nutritional support maintains body condition during prolonged illness, with feeding strategies adapted to encourage intake in inappetent horses. Plasma transfusion may be indicated for horses with severe hypoproteinemia. Gastroprotectants prevent stress-related gastric ulceration. Nursing care including regular monitoring, clean bedding, and environmental temperature control supports recovery. Thrombophlebitis prevention through catheter site rotation and monitoring protects venous access during extended treatment.

Rehabilitation and return to work following pleuropneumonia requires patience and graduated exercise introduction. Complete rest continues until fever resolves completely and respiratory function significantly improves. Hand walking begins when the horse is clinically stable, progressing gradually to turnout and eventually mounted exercise over weeks to months. Thoracic ultrasound reassessment confirms resolution of pleural fluid before advancing exercise intensity. Some horses develop reduced exercise tolerance from pulmonary scarring or pleural adhesions, requiring adjustment of performance expectations.

Treatment decision factors include severity of illness at presentation, facilities available for intensive care and thoracic drainage, owner financial resources for potentially extended treatment, and intended future use of the horse. Horses diagnosed early with prompt aggressive treatment have the best outcomes. Severely ill horses require referral to hospitals equipped for intensive care. Honest discussions about prognosis, treatment costs that may exceed tens of thousands of dollars, and potential long-term limitations help owners make informed decisions. Humane euthanasia may be appropriate for horses with overwhelming infection, poor treatment response, or when resources for adequate care are unavailable.

Recovery timeline for pleuropneumonia is typically prolonged, measured in months rather than weeks even for horses that ultimately return to full function. Initial improvement with fever resolution and appetite return may occur within one to two weeks of appropriate treatment, though pleural changes take much longer to resolve. Complete resolution of pleural fluid and inflammation typically requires three to six months. Return to athletic activity generally occurs six months to one year after diagnosis, with some horses requiring longer rehabilitation periods depending on the extent of pulmonary and pleural damage sustained.

Post-treatment care and monitoring extend for months following apparent clinical recovery. Regular thoracic ultrasound examinations track resolution of pleural fluid and adhesion formation, guiding decisions about exercise progression. Temperature monitoring continues throughout recovery to detect any recurrence of fever suggesting relapse or secondary infection. Appetite and body condition should steadily improve during recovery, with failure to regain weight prompting investigation for ongoing problems. Follow-up complete blood counts and fibrinogen measurements confirm resolution of inflammatory markers.

Prognosis factors influencing recovery include severity of illness at diagnosis, timeliness of treatment initiation, presence of bilateral versus unilateral involvement, and development of complications. Horses treated early before extensive pleural involvement have the best prognosis, with survival rates exceeding eighty percent and many returning to previous athletic function. Severe cases with bilateral involvement, lung abscessation, or delayed treatment have survival rates closer to fifty to seventy percent, with survivors more likely to have residual limitations. Response to initial treatment predicts ultimate outcome, with horses showing improvement within the first week having better prognosis.

Long-term soundness outlook depends on the degree of permanent pulmonary and pleural changes. Horses recovering with minimal adhesion formation often return to their previous level of athletic performance without detectable limitations. Those developing extensive pleural adhesions may have restricted lung expansion affecting maximum exercise capacity, potentially limiting participation in high-intensity sports. Pulmonary scarring from lung abscessation may similarly impair respiratory reserve. Respiratory function testing, if available, can objectively assess any residual limitations. Some recovered horses perform successfully at their previous levels while others require discipline changes accommodating reduced respiratory capacity.

Management practices to prevent pleuropneumonia focus primarily on reducing transport-related risk, the single most important predisposing factor. Limiting transport duration when possible reduces cumulative stress, with rest stops every four to six hours during long journeys allowing horses to lower their heads for airway drainage. Providing adequate space during transport allows more natural head positioning. Ensuring proper ventilation during transport prevents accumulation of respiratory irritants while avoiding direct drafts. Scheduling adequate rest periods following transport before resuming training allows respiratory defenses to recover.

Nutritional prevention supports immune function and respiratory tract health. Maintaining adequate hydration during and after transport preserves mucociliary clearance. Providing quality forage rather than grain during transport reduces dust exposure and maintains gut health during stress. Electrolyte supplementation may help maintain hydration during travel. Overall nutritional adequacy with appropriate vitamins and minerals supports immune function. Avoiding transport of horses in poor body condition when possible reduces susceptibility.

Exercise and conditioning considerations include allowing adequate recovery time after transport before intensive training resumes. Horses should rest for at least twenty-four to forty-eight hours after long-distance transport before returning to work. Monitoring temperature daily for one week following transport detects early fever. Avoiding training horses with any respiratory symptoms prevents progression to severe disease. Conditioning programs that avoid overtraining maintain rather than suppress immune function.

Environmental factors affecting pleuropneumonia risk can be modified through facility management. Excellent ventilation in barns reduces airborne pathogen concentration and respiratory irritant levels. Low-dust bedding and feeding practices minimize airway irritation. Quarantine of new arrivals prevents introduction of novel respiratory pathogens. Avoiding overcrowding reduces transmission pressure. Climate control during extreme temperatures protects horses from thermal stress that may impair immunity.

Vaccination and deworming protocols reduce pleuropneumonia risk by preventing conditions that predispose to bacterial infection. Vaccination against equine influenza and equine herpesvirus reduces viral respiratory infections that damage airways and allow bacterial invasion. Maintaining current vaccination is particularly important before transport or exposure to horses from multiple sources. Strategic deworming prevents parasitic damage and immunosuppression. While no vaccine specifically targets pleuropneumonia, protecting against predisposing conditions provides meaningful risk reduction.

Daily management adjustments for horses recovering from pleuropneumonia or at high risk emphasize respiratory health optimization and stress minimization. Housing in well-ventilated areas with low dust levels protects recovering airways. Using dust-free or low-dust bedding reduces particulate exposure. Hay should be soaked or steamed to minimize dust inhalation. Daily temperature monitoring continues throughout recovery to detect any recurrence. Careful observation of respiratory rate, effort, and character identifies any deterioration requiring veterinary attention.

Housing and turnout considerations during pleuropneumonia recovery balance the benefits of rest against the value of gentle movement for circulation and psychological wellbeing. Initial stall rest during acute illness gives way to hand walking as clinical improvement allows. Small paddock turnout follows hand walking, with gradual expansion of exercise privileges as recovery progresses. Avoiding turnout with other horses that might encourage excessive activity protects healing respiratory tissues. Climate control or shelter access protects against temperature extremes during vulnerable recovery periods.

Exercise modifications during and after pleuropneumonia are essential for complete recovery without setback. Complete rest continues throughout acute illness and early recovery phases. Hand walking typically begins once fever has resolved for several days and appetite has returned. Ground work and light longeing may begin weeks to months later as recovery progresses. Return to ridden work should not occur until thoracic ultrasound confirms resolution of pleural abnormalities. Gradual progression from walking to trotting to cantering over months allows assessment of exercise tolerance at each level.

Monitoring and ongoing care during extended recovery includes regular veterinary rechecks with thoracic ultrasound to track pleural resolution. Body weight should be recorded regularly to confirm appropriate condition improvement. Respiratory rate and effort at rest and with mild exercise provide ongoing assessment of pulmonary function. Completing full antibiotic courses despite clinical improvement prevents relapse. Owner communication with the veterinary team allows timely intervention if any concerns arise during the recovery period.

Quality of life and use considerations acknowledge that pleuropneumonia requires major commitment and may affect future athletic potential. Extended recovery periods interrupt training and competition schedules significantly. Some horses return to their previous level of performance while others require discipline changes or retirement to less demanding activities. Honest assessment of respiratory function following recovery helps set appropriate expectations. The financial and emotional investment required for treatment and recovery should be considered when making decisions about aggressive treatment versus euthanasia for severe cases.

Pleuropneumonia does not demonstrate breed predisposition, as risk relates primarily to management and environmental factors rather than genetic susceptibility. All horse breeds develop pleuropneumonia at similar rates when exposed to equivalent risk factors including long-distance transport, viral respiratory infection, and other predisposing conditions. Thoroughbreds, Warmbloods, Quarter Horses, Standardbreds, Arabians, draft breeds, and ponies all face this risk when circumstances favor infection development. No breed-specific screening or prevention protocols are indicated beyond good management practices applicable to all horses.

Use and discipline considerations reveal that horses in certain activities face increased pleuropneumonia risk due to management patterns rather than inherent breed characteristics. Racehorses frequently transported between tracks experience repeated exposure to transport-related risk factors. Show horses traveling extensively to competitions face similar cumulative risk. Sale horses transported to auctions encounter both transport stress and exposure to horses from multiple sources. Breeding stock shipped for breeding purposes experiences transport stress that may coincide with the immunomodulation of pregnancy. Any discipline involving frequent long-distance travel increases exposure.

Genetic testing and breeding recommendations are not applicable to pleuropneumonia since no hereditary component influences susceptibility. Breeding decisions need not account for pleuropneumonia history from a genetic standpoint. However, horses recovering from pleuropneumonia should complete full recovery before being used for breeding to ensure adequate health and to avoid pregnancy complications. Pregnant mares should receive particular attention to transport protocols and stress minimization to protect both mare and fetus. Mares with pleuropneumonia history may be candidates for low-stress breeding approaches such as artificial insemination to avoid shipping to breeding farms.

Commonly co-occurring conditions with pleuropneumonia include primary viral respiratory infections that frequently precede bacterial complications. Equine influenza and equine herpesvirus damage the respiratory epithelium, impairing defenses and allowing bacterial invasion that may progress to pleuropneumonia. Simple bacterial pneumonia without pleural involvement represents an earlier stage in the same disease spectrum, with pleuropneumonia developing when infection extends to the pleural space. Gastric ulceration frequently develops secondary to stress, decreased feed intake, and anti-inflammatory medication, warranting gastroprotectant therapy during treatment.

Conditions with similar symptoms that must be differentiated from pleuropneumonia include uncomplicated bacterial pneumonia, which shares many features but lacks pleural involvement visible on ultrasound. Hemothorax from trauma produces pleural fluid but with different characteristics on thoracocentesis. Neoplasia affecting the thorax may produce pleural effusion with distinct cytologic findings. Cardiac disease with pericardial effusion may produce some similar clinical signs. Aspiration pneumonia from choke or other causes presents similarly but with a different history. Thoracic ultrasound and fluid analysis typically allow accurate differentiation.

Potential complications of pleuropneumonia include abscessation within the lungs or pleural space, creating loculated pockets of infection resistant to systemic antibiotics and requiring drainage. Pulmonary fibrosis from extensive inflammation reduces functional lung capacity. Pleural adhesions restrict lung expansion, potentially limiting athletic performance permanently. Thrombophlebitis develops at venous catheter sites during prolonged treatment. Laminitis may occur secondary to systemic toxemia and endotoxin release. Cardiac complications including myocarditis and pericarditis occasionally develop. Death from septic shock, respiratory failure, or multi-organ dysfunction occurs in severe cases despite aggressive treatment.